A Phase 1 Safety, Tolerability, and Pharmacokinetics & Pharmacodynamics Study of Multiple- Dose BIVV009 in Patients With Chronic Immune Thrombocytopenia (ITP)
Latest Information Update: 26 Apr 2022
Price :
$35 *
At a glance
- Drugs Sutimlimab (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions
- Sponsors Bioverativ; True North Therapeutics
- 18 Mar 2022 Results presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 03 Mar 2021 Status changed from active, no longer recruiting to completed.
- 08 Dec 2020 Interim results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology